AMARIN CORP PLC\UK Proceeds from Issuance or Sale of Equity
AMARIN CORP PLC\UK (AMRN) reported Proceeds from Issuance or Sale of Equity of $121.20 million for the 0-month period ending 2013-07-12, per its 10-Q filed 2013-11-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2013-11-07
- 2013-07-12: Proceeds from Issuance or Sale of Equity 0 month $121.20M.
| Period end | Proceeds from Issuance or Sale of Equity 0 month |
|---|---|
| 2013-07-12 | $121.20M 10-Q · filed 2013-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |